Remodulin — Gross Profit
United Therapeutics Remodulin — Gross Profit decreased by 7.8% to $110.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.2%, from $124.40M to $110.50M. Over 4 years (FY 2021 to FY 2025), Remodulin — Gross Profit shows relatively stable performance with a 0.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher gross profit indicates strong pricing power and efficient production, whereas declining margins may indicate pricing pressure or rising input costs.
Detailed definition
Calculated as the total revenue from a specific product line minus the direct cost of sales associated with that product...
Peer comparison
Standard 'Gross Profit' metric applied at the product or segment level across the pharmaceutical industry.
uthr_segment_remodulin_gross_profitHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $131.40M | $118.50M | $103.90M | $124.50M | $123.40M | $106.50M | $111.80M | $114.50M | $119.90M | $119.30M | $102.90M | $120.10M | $134.50M | $115.00M | $121.10M | $124.40M | $120.40M | $112.80M | $119.90M | $110.50M |
| QoQ Change | — | -9.8% | -12.3% | +19.8% | -0.9% | -13.7% | +5.0% | +2.4% | +4.7% | -0.5% | -13.7% | +16.7% | +12.0% | -14.5% | +5.3% | +2.7% | -3.2% | -6.3% | +6.3% | -7.8% |
| YoY Change | — | — | — | — | -6.1% | -10.1% | +7.6% | -8.0% | -2.8% | +12.0% | -8.0% | +4.9% | +12.2% | -3.6% | +17.7% | +3.6% | -10.5% | -1.9% | -1.0% | -11.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's remodulin — gross profit?
- United Therapeutics (UTHR) reported remodulin — gross profit of $110.50M in Q1 2026.
- How has United Therapeutics's remodulin — gross profit changed year-over-year?
- United Therapeutics's remodulin — gross profit decreased by 11.2% year-over-year, from $124.40M to $110.50M.
- What is the long-term trend for United Therapeutics's remodulin — gross profit?
- Over 4 years (2021 to 2025), United Therapeutics's remodulin — gross profit has grown at a 0.1% compound annual growth rate (CAGR), from $475.80M to $477.50M.
- What does remodulin — gross profit mean?
- The profit remaining from product sales after subtracting the direct costs to make and sell the drug.